SOURCE: Ablynx

December 20, 2007 01:30 ET


GHENT, BELGIUM--(Marketwire - December 20, 2007) -

GHENT, Belgium, 20 December 2007 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its TNF-alpha partnership with Wyeth Pharmaceuticals has been extended for another year.

Wyeth and Ablynx are collaborating to discover and develop novel Nanobody®-based therapeutics against TNF-alpha. Wyeth has exclusive rights to develop and commercialise the anti-TNF-alpha Nanobodies® developed under the collaboration.

As part of the collaboration Ablynx receives research funding and would be entitled to future milestone payments and royalties upon commercialisation.

Dr. Edwin Moses, CEO and Chairman of Ablynx, commented: "We are very pleased with the progress of our partnership with Wyeth, which has world class capabilities in the development and commercialisation of biologics. We look forward to continuing our collaboration for another year. This is an important partnership for Ablynx and we are delighted to continue our joint efforts to advance the TNF-alpha Nanobody®-based programme to the next stage."

Dr. Frank Walsh, Executive Vice President, Head of Discovery Research of Wyeth Pharmaceuticals said: "We continue to be excited about the potential of Ablynx's Nanobody® technology as a platform for next-generation therapeutics targeted to TNF-alpha. We look forward to our ongoing collaboration with Ablynx with the goal of bringing new therapies to patients."

- ends -

For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, Holly Griffiths
t:   +44 (0)20 7457 2020
f:   +44 (0)20 7866 7900

Dr. Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information